Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoketoconazole randomized withdrawal study in endogenous Cushing's syndrome
2017-001219-35Phase 3Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levoketoconazole in Cushing's syndrome (3 arms), sponsored by Strongbridge Biopharma. Primary endpoint: Loss of therapeutic response after withdrawal to placebo versus continued levoketoconazole. Started Oct 2017; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2017-001219-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001219-35.